t-Butyl-3-pentylamin | 51609-05-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: t-Butyl-3-pentylamin
• 英文别名: N-(tert-butyl)-3-pentanamine；N-tert-butylpentan-3-amine
• CAS: 51609-05-3
• 化学式: C₉H₂₁N
• 分子量: 143.272
• InChiKey: SZAGYXMYNOXHSN-UHFFFAOYSA-N

物化性质

• 沸点：
  145 °C
• 密度：
  0.768±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  t-Butyl-3-pentylamin 、 2,6-二甲苯基异氰酸酯 在 苯甲醚 作用下， 生成 N-Dimethylphenyl-N'-t-butyl,N'-3-pentylharnstoff
  参考文献：
  名称：

  Urea dissociation. Measure of steric hindrance in secondary amines

  摘要：

  DOI：

  10.1021/jo00930a039
• 作为产物：
  描述：

  N-Dimethylphenyl-N'-t-butyl,N'-3-pentylharnstoff 在 苯甲醚 作用下， 生成 t-Butyl-3-pentylamin 、 2,6-二甲苯基异氰酸酯
  参考文献：
  名称：

  Urea dissociation. Measure of steric hindrance in secondary amines

  摘要：

  DOI：

  10.1021/jo00930a039

文献信息

• Thiazolyl mglur5 antagonists and methods for their use
  申请人：Cosford Nicholas D.

  公开号：US20090203903A1

  公开（公告）日：2009-08-13

  The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.

  一系列独特化合物的鉴定，由于它们在药物样性方面具有优势特性，包括在效力、药代动力学、选择性和体内受体占有性质方面具有优势特性。具体来说，选择一个由乙炔基连接到吡啶环的3位或嘧啶环的5位的1,3-噻唑-2-基环成员，其中环被选定取代基取代，将导致一种具有优越药物样性的化合物。该发明包括这些杂环化合物的药用盐形式，特别是氯化盐和三氟乙酸盐。
• FXR modulators
  申请人：Tularik Inc.

  公开号：US20020120137A1

  公开（公告）日：2002-08-29

  The present invention provides compounds, pharmaceutical compositions and methods that are useful in modulating the farnesoid X receptor (FXR). As FXR is involved in negatively controlling the expression level of cholesterol 7&agr;-hydroxylase (cyp7a), the rate-limiting enzyme involved in the oxidative metabolism of cholesterol into bile acids, the compounds described herein find utility in treating diseases associated with abnormally high or low cholesterol levels. In certain aspects, the FXR modulators (e.g., antagonists) described herein block the negative feed-back downregulation of cyp7a expression produced by certain cholic acids, the endogenous ligands for FXR. Moreover, as FXR forms heterodimers with the retinoid X receptor (RXR) in some cell types, modulation of the level of FXR activity in cells has a wide range of effects on a variety of biological processes which are mediated by RXR or other RXR-interacting proteins such as PPAR&ggr; and PPAR&agr;. Thus, compounds described herein are useful in treating other biological activities such as obesity, diabetes, lipid associated disorders, cancer, inflammatory disorders, disorders involving a disrupted or dysfunctional epidermal barrier, and various other metabolic disorders.

  本发明提供了化合物、制药组合物和方法，可用于调节法尼酰二烯醇X受体（FXR）。由于FXR参与负性调控胆固醇7α-羟化酶（cyp7a）的表达水平，该酶是将胆固醇氧化代谢成胆酸的速率限制酶，因此本文所述的化合物在治疗与胆固醇水平异常高或低相关的疾病方面具有实用价值。在某些方面，本文所述的FXR调节剂（例如拮抗剂）可阻断某些胆汁酸产生的cyp7a表达的负反馈下调。此外，由于FXR在某些细胞类型中与视黄酸X受体（RXR）形成异二聚体，因此调节细胞中FXR活性水平对由RXR或其他与RXR相互作用的蛋白质（例如PPARγ和PPARα）介导的各种生物过程具有广泛的影响。因此，本文所述的化合物在治疗其他生物活动，如肥胖症、糖尿病、与脂质有关的疾病、癌症、炎症性疾病、涉及破坏或功能障碍的表皮屏障的疾病以及各种其他代谢性疾病方面具有实用价值。
• COLORED CURABLE COMPOSITION, COLOR FILTER AND METHOD OF PRODUCING COLOR FILTER, SOLID-STATE IMAGE SENSOR AND LIQUID CRYSTAL DISPLAY DEVICE
  申请人：KANNA Shinichi

  公开号：US20110217636A1

  公开（公告）日：2011-09-08

  The present invention provides a colored curable composition including a phthalocyanine pigment, a dioxazine pigment, a dye, a polymerization initiator, a polymerizable compound and a solvent; and a colored curable composition including a phthalocyanine pigment, a dye multimer having a polymerizable group and a group derived from a dipyrromethene dye, a polymerization initiator, a polymerizable compound and a solvent.

  本发明提供了一种彩色可固化组合物，包括酞菁颜料、二氧化锰颜料、染料、聚合引发剂、可聚合化合物和溶剂；以及一种彩色可固化组合物，包括酞菁颜料、具有可聚合基团和源自二吡咯甲烷染料的染料多聚物、聚合引发剂、可聚合化合物和溶剂。
• Thiazolyl Mglur5 Antagonists and Methods for Their Use
  申请人：Cosford Nicholas D.

  公开号：US20110230526A1

  公开（公告）日：2011-09-22

  The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.

  本发明涉及一系列独特的化合物，由于它们具有优越的药物特性，因此具有优越的药物特性，包括效力和/或药代动力学和/或选择性和/或体内受体占有率特性。具体来说，选择一个1,3-噻唑-2-基环成员，通过乙炔基连接到吡啶环的3位或嘧啶环的5位，其中该环被选定的取代基取代，结果产生具有优越药物特性的化合物。本发明包括这些杂环化合物的药学上可接受的盐形式，特别是氯化物盐和三氟乙酸盐。
• THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE
  申请人：Cosford Nicholas D.

  公开号：US20120289696A1

  公开（公告）日：2012-11-15

  The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.

  本发明涉及一种独特的化合物系列的鉴定，由于这些化合物具有优越的药物性质，因此具有优越的效力、药代动力学、选择性和/或体内受体占用性质。具体而言，选择将1,3-噻唑-2-基环成员与乙炔基连接到吡啶环的3位或嘧啶环的5位，其中该环被选定的取代基取代，可得到具有优越药物性质的化合物。本发明包括这些杂环化合物的药用可接受盐形式，特别是氯化物盐和三氟乙酸盐。